What this means
This trial gave UBX0101 into the knee joint, once or more than once, in people with painful knee arthritis. It aimed to check safety and effects, but no results have been posted yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Completed
- Who can join
- Ages 40–85
- Where
- 7 sites, including Florida, Georgia, Missouri
The science
- Registered title
- A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee
- Trial ID
- NCT04229225 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Knee Osteoarthritis
- What is tested
- UBX0101, Placebo
- Sponsor
- Unity Biotechnology, Inc.
- Ages
- 40 Years to 85 Years
- Dates
- First posted Jan 18, 2020 · updated Oct 19, 2020
Registry summary
A study to assess safety, tolerability and clinical effects of single and repeat dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
Sites (7)
- Premier Medical Associates, The Villages, Florida, United States
- Drug Studies America, Marietta, Georgia, United States
- Sundance Clinical Research, LLC, St Louis, Missouri, United States
- Hassman Research Institute, Berlin, New Jersey, United States
- Rochester Clinical Research, Inc., Rochester, New York, United States
- Arcis Healthcare LLC dba Lowcountry Orthopaedics and Sports Medicine, North Charleston, South Carolina, United States
- First Surgical Hospital, Bellaire, Texas, United States
More aging trials in these states
Florida · Georgia · Missouri · New Jersey · New York · South Carolina · Texas